Old Revisions

These are the older revisons of the current document. To revert to an old revision, select it from below, click Edit this page and save it.

2022/04/30 11:32 Vigabatrin – changed pubmed syntax administrator@icnapedia.org -56 B (current)
2020/02/23 18:46 Vigabatrin – [Adverse drug reactions] icna +130 B
2020/02/23 18:15 Vigabatrin – [Dosage and titration] icna +6 B
2020/02/23 18:14 Vigabatrin – [Main disadvantages] icna +380 B
2020/02/23 18:04 Vigabatrin – [Main disadvantages] icna +14 B
2020/02/23 18:01 Vigabatrin – [Considerations in women] icna +241 B
2020/02/23 18:00 Vigabatrin – [Authorised indications] icna +130 B
2020/02/23 17:58 Vigabatrin – [Vigabatrin] icna +91 B
2020/02/23 17:56 Vigabatrin – [Clinical applications] icna +210 B
2020/02/23 17:54 Vigabatrin – [Adverse drug reactions] icna +33 B
2020/02/23 17:46 Vigabatrin – [Drug interactions] icna -6 B
2020/02/23 17:45 Vigabatrin – [Main mechanisms of action] icna -62 B
2020/02/23 17:39 Vigabatrin – [Main disadvantages] icna -3.6 KB
2020/02/23 17:39 Vigabatrin – created icna +10.3 KB